Ivax Glucovance ANDA Approved; Inventory Build-Up Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
The company holds first-to-file rights for generic of Bristol's antidiabetic, which lost marketing exclusivity Jan. 31.